.
MergerLinks Header Logo

Announced

NB Renaissance to invest in Neopharmed.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Domestic

Minority

pharmaceuticals companies

Friendly

Pharmaceuticals

Italy

Private Equity

Private

Acquisition

Pending

Synopsis

Edit

NB Renaissance, a private equity general partner firm, agreed to invest in Neopharmed, a provider of research, development and distribution of medicines. Ardian reinvests and together with NB Renaissance, jointly holding a majority stake with equal shares. Mediolanum Farmaceutici will maintain a significant stake in the company. Financial terms were not disclosed. "We are extremely proud of the relationship established with Alessandro Del Bono and with the entire management team of Neopharmed Gentili. As a result of our partnership, the company has achieved brilliant results over the past four years, and we are convinced there are numerous continued growth opportunities in Italy and abroad. We believe that this partnership with NB Renaissance will facilitate further consolidation and international development, while safeguarding the current corporate culture.” Nicolò Saidelli, Ardian Head of Italy and Deputy Head of Buyout.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US